Needham & Company
-
Needham & Company Maintains a 'Hold' on Cubist Pharmaceuticals (CBST); Review of Investor Day
-
Needham & Company Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); Dificid Hits Sales Goal under Cubist Collaboration
-
Needham & Company maintains a 'Hold' on Cubist Pharmaceuticals (CBST); Cubicin Sales Beat; Awaiting Progression
-
Needham & Company Maintains a 'Hold' on Cubist Pharmaceuticals (CBST); 4Q11 Review. U.S. Cubicin Sales Guidance for 2012 In-line with Our Expectations
-
Needham & Company 2012 Biotech Preview
-
Needham & Company Reiterates a 'Buy' on Cubist Pharmaceuticals (CBST); 3Q11 U.S. Cubicin Sales Well Above Expectations
-
Needham & Company Reiterates 'Buy' on Optimer Pharmaceuticals (OPTR); Collaborator/Competitor Cubist Confirms Plans to Bring CB-315 into Phase 3
-
Needham & Company Maintains a 'Buy' on Cubist Pharmaceuticals (CBST); Favorably Inclined Towards the Stock
-
Needham & Company Reiterates a 'Buy' on Cubist Pharmaceuticals (CBST); 2Q11 Cubicin Sales Slightly Above Expectations and Guidance Raised for the Year
-
Needham & Company Reiterates a 'Buy' on Cubist Pharmaceuticals (CBST); U.S. and International Cubicin Sales Beat Expectations
-
Needham & Company Reiterates a 'Buy' on Cubist Pharmaceuticals (CBST); Teva and Cubist Settle Cubicin Litigation
-
Needham & Company Reiterates a 'Buy' on Cubist Pharmaceuticals (CBST); '11 Cubicin Guidance Modestly Lower than Anticipated; Litigation is Principal Driver of Stock
-
Needham & Company Reiterates a 'Buy' on Cubist Pharmaceuticals (CBST); Analyst Day Review
-
Needham & Company Reiterates a 'Buy' on Cubist Pharmaceuticals (CBST); 2Q10 Review. Cubicin Sales and EPS Beat Estimates
-
Needham & Company Reiterates a 'Buy' on Cubist Pharmaceuticals (CBST); Focused on Upcoming Pipeline News
-
Needham & Company Maintains Bullish Stance on Cubist Pharmaceuticals (CBST) Despite CB-929 Termination
-
Needham & Co Reiterates a 'Buy' on Cubist Pharmaceuticals (CBST)
-
Needham & Co Reiterates a 'Buy' Rating on Cubist Pharmaceuticals (CBST), Raises Earnings Estimates and Price Target
-
Needham Starts Cubist Pharmaceuticals (CBST) at Buy

